Cognivia CEO Dominique Demolle, PhD, Named Among 2022’s Most Inspiring People by PharmaVoice
We are pleased to share that our very own Dominique Demolle, CEO, has been recognized as one of…
News
News
News
NEW Paper: Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials
Cognivia team members contribute critical elements to a recent paper published in Innovations in Clinical Neuroscience. Cognivia co-authored a…
News
New Cognivia article in Drug Development & Discovery on “Cracking Down on the Rising Costs of Drug Development”
Drug development has changed significantly throughout the past 2 decades – including great leaps forward in areas from…
News
New Cognivia interview in Medical News Today on COVID-19 vaccines and ‘nocebo’ effect
New research suggests that a high percentage of reported side effects from COVID-19 vaccines may be due to what’s…
News
New Cognivia article in Applied Clinical Trials on “Using Machine Learning to Predict Placebo Response and Increase Clinical Trial Success”
The overall risk of clinical trial failure is still too high – meaning more repeat trials, lost timelines…
News
New Cognivia publication on the use of composite covariates to understand complex data in clinical trial data analysis
Covariates are typically used to control for factors that may impact the measurement of outcomes, particularly to describe individual patient characteristics that may or may not relate to treatment response. In fact, all patient baseline characteristics collected are potential covariates linked with the patient’s outcome.